Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research

James M. Foran, Steven Z. Pavletic, Brent R. Logan, Manza A. Agovi-Johnson, Waleska S. Pérez, Brian J. Bolwell, Martin Bornhäuser, Christopher N. Bredeson, Mitchell S. Cairo, Bruce M. Camitta, Edward A. Copelan, Jason Dehn, Robert P. Gale, Biju George, Vikas Gupta, Gregory A. Hale, Hillard M. Lazarus, Mark R. Litzow, Dipnarine Maharaj, David I. MarksRodrigo Martino, Richard Maziarz, Jacob M. Rowe, Philip A. Rowlings, Bipin N. Savani, Mary Lynn Savoie, Jeffrey Szer, Edmund K. Waller, Peter H. Wiernik, Daniel J. Weisdorf

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoietic stem cell transplantation (auto-HCT) is very poor. We studied the outcomes of 302 patients who underwent secondary allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor (URD) using either myeloablative (n= 242) or reduced-intensity conditioning (RIC; n= 60) regimens reported to the Center for International Blood and Marrow Transplantation Research. After a median follow-up of 58 months (range, 2 to 160 months), the probability of treatment-related mortality was 44% (95% confidence interval [CI], 38%-50%) at 1-year. The 5-year incidence of relapse was 32% (95% CI, 27%-38%), and that of overall survival was 22% (95% CI, 18%-27%). Multivariate analysis revealed a significantly better overal survival with RIC regimens (hazard ratio [HR], 0.51; 95% CI, 0.35-0.75; P 18 months) from auto-HCT to URD allo-HCT was associated with significantly lower riak of relapse (HR, 0.19; 95% CI, 0.09-0.38; P

Original languageEnglish (US)
Pages (from-to)1102-1108
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume19
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Unrelated Donors
Autologous Transplantation
Homologous Transplantation
Acute Myeloid Leukemia
Transplantation
Bone Marrow
Confidence Intervals
Research
Hematopoietic Stem Cell Transplantation
Cell Transplantation
Survival
Recurrence
Multivariate Analysis
Mortality
Incidence

Keywords

  • Acute myelogenous leukemia
  • Allogeneic
  • Autologous
  • Transplantation
  • Unrelated donor

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia : A Study from the Center for International Blood and Marrow Transplantation Research. / Foran, James M.; Pavletic, Steven Z.; Logan, Brent R.; Agovi-Johnson, Manza A.; Pérez, Waleska S.; Bolwell, Brian J.; Bornhäuser, Martin; Bredeson, Christopher N.; Cairo, Mitchell S.; Camitta, Bruce M.; Copelan, Edward A.; Dehn, Jason; Gale, Robert P.; George, Biju; Gupta, Vikas; Hale, Gregory A.; Lazarus, Hillard M.; Litzow, Mark R.; Maharaj, Dipnarine; Marks, David I.; Martino, Rodrigo; Maziarz, Richard; Rowe, Jacob M.; Rowlings, Philip A.; Savani, Bipin N.; Savoie, Mary Lynn; Szer, Jeffrey; Waller, Edmund K.; Wiernik, Peter H.; Weisdorf, Daniel J.

In: Biology of Blood and Marrow Transplantation, Vol. 19, No. 7, 07.2013, p. 1102-1108.

Research output: Contribution to journalArticle

Foran, JM, Pavletic, SZ, Logan, BR, Agovi-Johnson, MA, Pérez, WS, Bolwell, BJ, Bornhäuser, M, Bredeson, CN, Cairo, MS, Camitta, BM, Copelan, EA, Dehn, J, Gale, RP, George, B, Gupta, V, Hale, GA, Lazarus, HM, Litzow, MR, Maharaj, D, Marks, DI, Martino, R, Maziarz, R, Rowe, JM, Rowlings, PA, Savani, BN, Savoie, ML, Szer, J, Waller, EK, Wiernik, PH & Weisdorf, DJ 2013, 'Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research', Biology of Blood and Marrow Transplantation, vol. 19, no. 7, pp. 1102-1108. https://doi.org/10.1016/j.bbmt.2013.04.022
Foran, James M. ; Pavletic, Steven Z. ; Logan, Brent R. ; Agovi-Johnson, Manza A. ; Pérez, Waleska S. ; Bolwell, Brian J. ; Bornhäuser, Martin ; Bredeson, Christopher N. ; Cairo, Mitchell S. ; Camitta, Bruce M. ; Copelan, Edward A. ; Dehn, Jason ; Gale, Robert P. ; George, Biju ; Gupta, Vikas ; Hale, Gregory A. ; Lazarus, Hillard M. ; Litzow, Mark R. ; Maharaj, Dipnarine ; Marks, David I. ; Martino, Rodrigo ; Maziarz, Richard ; Rowe, Jacob M. ; Rowlings, Philip A. ; Savani, Bipin N. ; Savoie, Mary Lynn ; Szer, Jeffrey ; Waller, Edmund K. ; Wiernik, Peter H. ; Weisdorf, Daniel J. / Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia : A Study from the Center for International Blood and Marrow Transplantation Research. In: Biology of Blood and Marrow Transplantation. 2013 ; Vol. 19, No. 7. pp. 1102-1108.
@article{a8fa64a3c3554baa9bd6cb811a4f62ec,
title = "Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research",
abstract = "The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoietic stem cell transplantation (auto-HCT) is very poor. We studied the outcomes of 302 patients who underwent secondary allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor (URD) using either myeloablative (n= 242) or reduced-intensity conditioning (RIC; n= 60) regimens reported to the Center for International Blood and Marrow Transplantation Research. After a median follow-up of 58 months (range, 2 to 160 months), the probability of treatment-related mortality was 44{\%} (95{\%} confidence interval [CI], 38{\%}-50{\%}) at 1-year. The 5-year incidence of relapse was 32{\%} (95{\%} CI, 27{\%}-38{\%}), and that of overall survival was 22{\%} (95{\%} CI, 18{\%}-27{\%}). Multivariate analysis revealed a significantly better overal survival with RIC regimens (hazard ratio [HR], 0.51; 95{\%} CI, 0.35-0.75; P 18 months) from auto-HCT to URD allo-HCT was associated with significantly lower riak of relapse (HR, 0.19; 95{\%} CI, 0.09-0.38; P",
keywords = "Acute myelogenous leukemia, Allogeneic, Autologous, Transplantation, Unrelated donor",
author = "Foran, {James M.} and Pavletic, {Steven Z.} and Logan, {Brent R.} and Agovi-Johnson, {Manza A.} and P{\'e}rez, {Waleska S.} and Bolwell, {Brian J.} and Martin Bornh{\"a}user and Bredeson, {Christopher N.} and Cairo, {Mitchell S.} and Camitta, {Bruce M.} and Copelan, {Edward A.} and Jason Dehn and Gale, {Robert P.} and Biju George and Vikas Gupta and Hale, {Gregory A.} and Lazarus, {Hillard M.} and Litzow, {Mark R.} and Dipnarine Maharaj and Marks, {David I.} and Rodrigo Martino and Richard Maziarz and Rowe, {Jacob M.} and Rowlings, {Philip A.} and Savani, {Bipin N.} and Savoie, {Mary Lynn} and Jeffrey Szer and Waller, {Edmund K.} and Wiernik, {Peter H.} and Weisdorf, {Daniel J.}",
year = "2013",
month = "7",
doi = "10.1016/j.bbmt.2013.04.022",
language = "English (US)",
volume = "19",
pages = "1102--1108",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia

T2 - A Study from the Center for International Blood and Marrow Transplantation Research

AU - Foran, James M.

AU - Pavletic, Steven Z.

AU - Logan, Brent R.

AU - Agovi-Johnson, Manza A.

AU - Pérez, Waleska S.

AU - Bolwell, Brian J.

AU - Bornhäuser, Martin

AU - Bredeson, Christopher N.

AU - Cairo, Mitchell S.

AU - Camitta, Bruce M.

AU - Copelan, Edward A.

AU - Dehn, Jason

AU - Gale, Robert P.

AU - George, Biju

AU - Gupta, Vikas

AU - Hale, Gregory A.

AU - Lazarus, Hillard M.

AU - Litzow, Mark R.

AU - Maharaj, Dipnarine

AU - Marks, David I.

AU - Martino, Rodrigo

AU - Maziarz, Richard

AU - Rowe, Jacob M.

AU - Rowlings, Philip A.

AU - Savani, Bipin N.

AU - Savoie, Mary Lynn

AU - Szer, Jeffrey

AU - Waller, Edmund K.

AU - Wiernik, Peter H.

AU - Weisdorf, Daniel J.

PY - 2013/7

Y1 - 2013/7

N2 - The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoietic stem cell transplantation (auto-HCT) is very poor. We studied the outcomes of 302 patients who underwent secondary allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor (URD) using either myeloablative (n= 242) or reduced-intensity conditioning (RIC; n= 60) regimens reported to the Center for International Blood and Marrow Transplantation Research. After a median follow-up of 58 months (range, 2 to 160 months), the probability of treatment-related mortality was 44% (95% confidence interval [CI], 38%-50%) at 1-year. The 5-year incidence of relapse was 32% (95% CI, 27%-38%), and that of overall survival was 22% (95% CI, 18%-27%). Multivariate analysis revealed a significantly better overal survival with RIC regimens (hazard ratio [HR], 0.51; 95% CI, 0.35-0.75; P 18 months) from auto-HCT to URD allo-HCT was associated with significantly lower riak of relapse (HR, 0.19; 95% CI, 0.09-0.38; P

AB - The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoietic stem cell transplantation (auto-HCT) is very poor. We studied the outcomes of 302 patients who underwent secondary allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor (URD) using either myeloablative (n= 242) or reduced-intensity conditioning (RIC; n= 60) regimens reported to the Center for International Blood and Marrow Transplantation Research. After a median follow-up of 58 months (range, 2 to 160 months), the probability of treatment-related mortality was 44% (95% confidence interval [CI], 38%-50%) at 1-year. The 5-year incidence of relapse was 32% (95% CI, 27%-38%), and that of overall survival was 22% (95% CI, 18%-27%). Multivariate analysis revealed a significantly better overal survival with RIC regimens (hazard ratio [HR], 0.51; 95% CI, 0.35-0.75; P 18 months) from auto-HCT to URD allo-HCT was associated with significantly lower riak of relapse (HR, 0.19; 95% CI, 0.09-0.38; P

KW - Acute myelogenous leukemia

KW - Allogeneic

KW - Autologous

KW - Transplantation

KW - Unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=84879394074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879394074&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2013.04.022

DO - 10.1016/j.bbmt.2013.04.022

M3 - Article

C2 - 23632091

AN - SCOPUS:84879394074

VL - 19

SP - 1102

EP - 1108

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 7

ER -